Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis.

MLA

Hum, Ryan M., et al. “Non-Trough Adalimumab and Certolizumab Drug Levels Associated with a Therapeutic EULAR Response in Adherent Patients with Rheumatoid Arthritis.” Rheumatology (Oxford, England), vol. 62, no. 6, June 2023, pp. 2090–97. EBSCOhost, https://doi.org/10.1093/rheumatology/keac564.

APA

Hum, R. M., Ho, P., Nair, N., Jani, M., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Plant, D., & Barton, A. (2023). Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis. Rheumatology (Oxford, England), 62(6), 2090–2097. https://doi.org/10.1093/rheumatology/keac564

Chicago

Hum, Ryan M, Pauline Ho, Nisha Nair, Meghna Jani, Ann W Morgan, John D Isaacs, Anthony G Wilson, Kimme L Hyrich, Darren Plant, and Anne Barton. 2023. “Non-Trough Adalimumab and Certolizumab Drug Levels Associated with a Therapeutic EULAR Response in Adherent Patients with Rheumatoid Arthritis.” Rheumatology (Oxford, England) 62 (6): 2090–97. doi:10.1093/rheumatology/keac564.